Daratumumab is a humanized IgG1k monoclonal antibody that targets the CD38 epitope, which is a transmembrane glycoprotein that is expressed on multiple immune system cell types and in hematological malignancies, including MM. The gene discussed is CD38; the disease is Miyoshi myopathy.